ライフサイエンスコーパス: bromodeoxyuridine

1 of proliferating satellite cells labeled by bromodeoxyuridine.

2 confirmed by their nuclear incorporation of bromodeoxyuridine.

3 preceded by 2 hour of pulse-labeling with 5-bromodeoxyuridine.

4 d cells expressed cyclin B1 and incorporated bromodeoxyuridine.

5 d on incorporation of the thymidine analogue bromodeoxyuridine.

6 ients studied by in vivo pulse labeling with bromodeoxyuridine.

7 on cell production using the S-phase marker bromodeoxyuridine.

8 c segregation is tracked by incorporation of bromodeoxyuridine.

9 ch has some technical advantages over use of bromodeoxyuridine.

10 monidazole and cellular proliferation marker bromodeoxyuridine 1 h before sacrifice.

11 rough proliferation: 2.1+/-0.3% incorporated bromodeoxyuridine 2 hours after a single injection, and

12 ks 24 hours and 7 days after an injection of bromodeoxyuridine (2 and 8 days posthatch, respectively)

13 e division, all animals were inoculated with bromodeoxyuridine 24 h prior to sampling.

14 A in these glands with a different marker, 5-bromodeoxyuridine (5BrdU), resulted in the appearance of

15 iferation was determined by incorporation of bromodeoxyuridine and [3H]thymidine, fluorescence-activa

16 In vivo experiments, using bromodeoxyuridine and cell-specific markers, and ex vivo

17 small numbers of cells are doubly label for bromodeoxyuridine and olfactory marker protein, indicati

18 cells with combined immunohistochemistry for bromodeoxyuridine and retinal neuron and photoreceptor-s

19 on (types I and III) and incorporated more 5-bromodeoxyuridine and TUNEL staining compared with unsti

20 Distribution of bromodeoxyuridine and two additional adult neurogenesis

21 was documented by increased incorporation of bromodeoxyuridine and was attributed to the hypergastrin

22 ucleotides that are relatively large (dT and bromodeoxyuridine) and/or have a stable N-glycosylic bon

23 progastrin increased the number of CD44(+), bromodeoxyuridine+, and NUMB(+) cells, indicating an inc

24 , Ki-67, proliferating cell nuclear antigen, bromodeoxyuridine, and caspase-Glo 3/7 assays.

25 ularity were visualized using Hoechst 33342, bromodeoxyuridine, and CD31 staining, respectively.

26 analyzed by histology, for incorporation of bromodeoxyuridine, and for expression of the surface muc

27 ibutions of pimonidazole, GLUT-1 expression, bromodeoxyuridine, and Hoechst 33342 as visualized by im

28 ed thyroid cell number, the incorporation of bromodeoxyuridine, and the phosphorylation of retinoblas

29 weight ratio and showed increased numbers of bromodeoxyuridine- and phosphorylated histone H3-positiv

30 ated by a significant increase in numbers of bromodeoxyuridine- and Ulex europaeus-positive cells, bu

31 istinct detection procedures, one using anti-bromodeoxyuridine antibodies and the other using a 5-eth

32 We measured incorporation of bromodeoxyuridine as a marker of proliferation and phosp

33 Our studies using [(3)H]thymidine and bromodeoxyuridine as markers of DNA synthesis indicate t

34 and those that occur after treatment with 5-bromodeoxyuridine, as these mutations are also drastical

35 henyl)-2-(4-sulfophenyl)-2H-tet razolium and bromodeoxyuridine assay (MTS)] at doses between 0.001 an

36 henyl)-2-(4-sulfophenyl)-2H-tetr azolium and bromodeoxyuridine assays.

37 Newly produced cells were labeled by bromodeoxyuridine at approximately 1 week (P18-20) after

38 with markers of proliferation (ie, Ki-67 or bromodeoxyuridine) at estrus was significantly increased

39 Injections of the S-phase marker bromodeoxyuridine between postnatal days 3 and 14 showed

40 Using 5'-bromodeoxyuridine birth dating we established that mouse

41 By using bromodeoxyuridine birth dating, we found that the bullwh

42 Bromodeoxyuridine birth tracing and spatiotemporal track

43 By bromodeoxyuridine birthdating cells in green fluorescent

44 t 108 hours after gentamicin (36 hours after bromodeoxyuridine (BrdU) administration), as demonstrate

45 cord and label with the proliferation marker bromodeoxyuridine (BrdU) after a lesion.

46 Using the mitotic indicator bromodeoxyuridine (BrdU) and a retroviral vector, we fou

47 neurogenesis by labeling newborn cells with bromodeoxyuridine (BrdU) and confirming their neuronal l

48 A synthesis as indicated by incorporation of bromodeoxyuridine (BrdU) and expression of G1/S-phase ce

49 injection of the DNA synthesis phase marker bromodeoxyuridine (BrdU) and killed at varying survival

50 urs after lesioning, birds were administered bromodeoxyuridine (BrdU) and sacrificed 2 hours, 1 day,

51 cells in adult rats with the S-phase marker bromodeoxyuridine (BrdU) and used neuronal markers to ch

52 labeling new cells with the thymidine analog bromodeoxyuridine (BrdU) and using immunohistochemical m

53 ibitors is cytotoxic and cytostatic based on bromodeoxyuridine (BrdU) assay, propidium iodide (PI) st

54 ently we administered a cell cycle marker, 5-bromodeoxyuridine (BrdU) at early, middle or late period

55 Embryos were labeled cumulatively with bromodeoxyuridine (BrdU) delivered by an osmotic minipum

56 animals were injected intraperitoneally with bromodeoxyuridine (BrdU) every 2 hours for 12 hours, fol

57 Bromodeoxyuridine (BrdU) fate-tracing experiments demons

58 Bromodeoxyuridine (BrdU) feeding experiments demonstrate

59 etermined by labeling DNA of adult mice with bromodeoxyuridine (BrdU) for 3 days.

60 ne ([(3)H]dT) and the later developed analog bromodeoxyuridine (BrdU) have revolutionized our ability

61 Immunofluorescence in situ hybridization and bromodeoxyuridine (BrdU) incorporation analysis showed t

62 ting and inflammatory cells were detected by bromodeoxyuridine (BrdU) incorporation and anti-CD45 sta

63 es, MASH1 transduction resulted in increased bromodeoxyuridine (BrdU) incorporation and clonal colony

64 Detection of proliferating cells based on bromodeoxyuridine (BrdU) incorporation and determination

65 fect of VEGFB gene knockout (KO) in mice, on bromodeoxyuridine (BrdU) incorporation and expression of

66 monitored in rat lens epithelial explants by bromodeoxyuridine (BrdU) incorporation and expression of

67 combination with GSK-3 inhibition to enhance bromodeoxyuridine (BrdU) incorporation and Ki-67 express

68 with controls, as assessed by hepatocellular bromodeoxyuridine (BrdU) incorporation and mitotic frequ

69 6p22 amplicon strongly reduced the extent of bromodeoxyuridine (BrdU) incorporation and the rate of c

70 itor cells are in the G2/M cell cycle phase, bromodeoxyuridine (BrdU) incorporation demonstrated enha

71 he pro-mitotic growth factors with that of 5-bromodeoxyuridine (BrdU) incorporation to determine if e

72 5-bromodeoxyuridine (BrdU) incorporation was used to exami

73 An MTS assay, cell counts, and bromodeoxyuridine (BrdU) incorporation were used to dete

74 Cell proliferation was assessed by bromodeoxyuridine (BrdU) incorporation, and cell viabili

75 tion 18 +/- 2% above control, as assessed by bromodeoxyuridine (BrdU) incorporation, and reduced star

76 monitored in rat lens epithelial explants by bromodeoxyuridine (BrdU) incorporation.

77 nt of granule cell survival was monitored by bromodeoxyuridine (BrdU) incorporation.

78 on histone deacetylation and hepatocellular bromodeoxyuridine (BrdU) incorporation.

79 kinetics using H2B-GFP label retention and 5-bromodeoxyuridine (BrdU) incorporation.

80 t increase in proliferation as determined by bromodeoxyuridine (BrdU) incorporation; however, the abs

81 All mice were subjected to bromodeoxyuridine (BrdU) injection and sacrificed at dif

82 When evaluated 1 week after bromodeoxyuridine (BrdU) injection, approximately ten ti

83 Bromodeoxyuridine (BrdU) injections revealed an increase

84 y before euthanization, the rabbits received bromodeoxyuridine (BrdU) injections.

85 CLS expression inhibits the incorporation of bromodeoxyuridine (BrdU) into DNA, an effect proposed to

86 Bromodeoxyuridine (BrdU) is broadly used in neuroscience

87 ed rats, as determined using both cumulative bromodeoxyuridine (BrdU) labeling as well as labeling wi

88 The l-DOPA exposure decreased bromodeoxyuridine (BrdU) labeling in the lateral ganglio

89 Bromodeoxyuridine (BrdU) labeling indicated the same num

90 Bromodeoxyuridine (BrdU) labeling of cells, a marker for

91 Using bromodeoxyuridine (BrdU) labeling of newly generated cel

92 of p53 preceded tumor development; however, bromodeoxyuridine (BrdU) labeling of normal hepatic tiss

93 Bromodeoxyuridine (BrdU) labeling of proliferating cells

94 We then used bromodeoxyuridine (BrdU) labeling to see whether amacrin

95 Using in vivo bromodeoxyuridine (BrdU) labeling, a tubular cell popula

96 Transgene expression, bromodeoxyuridine (BrdU) labeling, and stem cell marker

97 5-Bromodeoxyuridine (BrdU) labeling, proliferating cell nu

98 he transplantation and 6-OHDA was tracked by bromodeoxyuridine (BrdU) labeling.

99 ly with a combination of both retroviral and bromodeoxyuridine (BrdU) labeling.

100 egion are actively cycling, as visualized by bromodeoxyuridine (BrdU) labeling.

101 urons, preweanlings were given injections of bromodeoxyuridine (BrdU) on postnatal day 6 (P6) or P21.

102 microscopy (EM) of adult mice that received bromodeoxyuridine (BrdU) or [3H]thymidine for several we

103 In agreement, bromodeoxyuridine (BrdU) pulse-chase analysis demonstrat

104 o approaches using incisor organ culture and bromodeoxyuridine (BrdU) pulse-chase experiments to iden

105 ed in vivo using thymidine analogues such as bromodeoxyuridine (BrdU) to label DNA synthesis during t

106 0 weekly injections of the thymidine analog, bromodeoxyuridine (BrdU) to mark new cells.

107 Forty-eight hour 5-bromodeoxyuridine (BrdU) uptake (used as an index of pro

108 se in cellular proliferation, as measured by bromodeoxyuridine (BrdU) uptake, and an increase in casp

109 Cell-cycle-associated markers consisted of bromodeoxyuridine (BrdU) uptake, and immunolabeling for

110 Bromodeoxyuridine (BrdU) was added to all the microcosms

111 Bromodeoxyuridine (BrdU) was administered (150 mg/kg x 3

112 Bromodeoxyuridine (BrdU) was administered 1 h, 2 days or

113 Bromodeoxyuridine (BrdU) was administered for various pe

114 Bromodeoxyuridine (BrdU) was administered to mice 3 days

115 virus (SIV) infection, the nucleoside analog bromodeoxyuridine (BrdU) was administered to six natural

116 Bromodeoxyuridine (BrdU) was given systemically to label

117 -CRM(197), MenC-PS, or saline; subsequently, bromodeoxyuridine (BrdU) was injected daily intraperiton

118 Bromodeoxyuridine (BrdU) was injected to label dividing

119 Bromodeoxyuridine (BrdU) was provided to mice continuous

120 ricular (icv) delivery of the mitotic marker bromodeoxyuridine (BrdU) we demonstrate that new cells a

121 By using a marker of cell division, bromodeoxyuridine (BrdU), in combination with several ma

122 ased proliferative activity assessed using 5-bromodeoxyuridine (BrdU), Ki-67, and c-Myc relative to n

123 Following incubation of damaged tissue with bromodeoxyuridine (BrdU), labeled nuclei were confined s

124 After an intraperitoneal injection of bromodeoxyuridine (BrdU), similar numbers of BrdU-positi

125 d nitrogen 337 nm UVA laser with and without bromodeoxyuridine (BrdU), the nanosecond and picosecond

126 A thymidine analogue, bromodeoxyuridine (BrdU), was added to the microcosms an

127 n this study, a non-native chemical species, bromodeoxyuridine (BrdU), was imaged within single HeLa

128 mmunolocalization of the nucleotide analogue bromodeoxyuridine (BrdU), we were able to follow replica

129 neurogenesis by intraperitoneal injection of bromodeoxyuridine (BrdU), which labels newborn neurons,

130 rease in epidermal turnover measured using a bromodeoxyuridine (BrdU)-based transit assay.

131 I-specific HDAC inhibitor valproic acid into bromodeoxyuridine (BrdU)-infused rats inhibited the incr

132 1(177-244)) resulted in a 4-fold increase of bromodeoxyuridine (BrDU)-labeled cells, suggesting that

133 reveal both internal L1 and L2 epitopes and bromodeoxyuridine (BrdU)-labeled encapsidated DNA is dep

134 ion cell nuclear antigen (PCNA)-positive and bromodeoxyuridine (BrdU)-labeled hepatocytes.

135 e substantiate here that I3 colocalizes with bromodeoxyuridine (BrdU)-labeled nascent viral genomes a

136 beta-cells from 1.5 +/- 0.3 to 4.0 +/- 0.8% bromodeoxyuridine (BrdU)-positive) beta-cells.

137 ONT) after injection with the S-phase marker bromodeoxyuridine (BrdU).

138 retain labels such as the thymidine analog 5-bromodeoxyuridine (BrdU).

139 ted proteins of RPE cells as demonstrated by bromodeoxyuridine (BrdU).

140 with halogenated thymidine analogs, such as bromodeoxyuridine (BrdU).

141 For mitotic labeling, bromodeoxyuridine (BrdU, 100 mg/kg) was administered twi

142 y was performed to measure the expression of bromodeoxyuridine (BrdU, a marker for cell proliferation

143 le adult rats were injected with one dose of bromodeoxyuridine (BrdU; 200 mg/kg), to label one popula

144 ere identified by nuclear incorporation of 5-bromodeoxyuridine (BrdU; 7-day minipump infusion).

145 Cytogenesis was examined at PD50 (through bromodeoxyuridine [BrdU] labeling) and survival of these

146 s between newly generated cells (marked with bromodeoxyuridine [BrdU]) and those expressing brain-der

147 otype of three constitutively proliferating (bromodeoxyuridine [BrdU]+) cell populations, including a

148 l proliferation as measured by the number of bromodeoxyuridine+ (BrdU+) cells (26.4%) compared with t

149 ssDNA oligonucleotides containing bromodeoxyuridine, BrdU-photoaptamers, are rapidly emerg

150 Bromodeoxyuridine (BrdUrd) immunolabeling and enzyme-lin

151 r flow cytometric analyses show pX-dependent bromodeoxyuridine (BrdUrd) incorporation in 4pX-1 cells

152 ociated beta-galactosidase activity, reduced bromodeoxyuridine (BrdUrd) incorporation, and reduced co

153 4-1BBL-stimulated OT-1 group showed enhanced bromodeoxyuridine (BrdUrd) incorporation, suggesting ong

154 Bromodeoxyuridine (BrdUrd) labeling studies showed that

155 Compared with control colonocytes [bromodeoxyuridine (BrdUrd), 2.2+/-1.2%], azoxymethane si

156 placebo by scanning electron microscopy and bromodeoxyuridine/CD31 labeling, respectively.

157 Flow cytometry and bromodeoxyuridine cell proliferation assays showed that

158 9cRA enhanced the proliferation of bromodeoxyuridine (+) cells in the subventricular zone (

159 ntation assays and in vivo administration of bromodeoxyuridine coupled to flow cytometry assays to as

160 Labeling of proliferating cells with bromodeoxyuridine demonstrated that the matrix keratinoc

161 cts, we have adapted an iododeoxyuridine and bromodeoxyuridine double labeling protocol for use in th

162 ) is greater for substrates that are larger (bromodeoxyuridine, dT) or have a more stable N-glycosidi

163 ment resulted in a decrease in the number of bromodeoxyuridine(+) (early), MAC387(+) (late), CD68(+)

164 DNA synthesis was analyzed by bromodeoxyuridine enzyme-linked immunosorbent assay.

165 ubulin-positive cells continue to label with bromodeoxyuridine even after 5 d of incubation.

166 cally labeled by sustained rather than acute bromodeoxyuridine exposure.

167 ere confirmed in short-term incubations with bromodeoxyuridine followed by CARD-FISH.

168 A separate cohort of mice received bromodeoxyuridine for detection of regeneration.

169 oliferation was measured by incorporation of bromodeoxyuridine, Foxf2 and Sfrp1 were localized by imm

170 Anti-5-bromodeoxyuridine immunolabeling revealed a significant

171 rands: lambda exonuclease digestion and anti-bromodeoxyuridine immunoprecipitation.

172 t first 8 weeks, after depletion of DCX- and bromodeoxyuridine-immunoreactive cells in the SVZ and de

173 d by increased number of cells incorporating bromodeoxyuridine in the whole population and increased

174 r labeling showed decreased incorporation of bromodeoxyuridine in thyroid tumor cells of Thrb(PV/PV)-

175 Bromodeoxyuridine incorporation (in vivo) and p16(INK4a)

176 lls with Ki67 and newly generated cells with bromodeoxyuridine incorporation 3 months after the injec

177 levated proliferation rates as assessed by 5-bromodeoxyuridine incorporation and cell-cycle analysis.

178 se cell frequencies and phenotype by ex vivo bromodeoxyuridine incorporation and flow-cytometric anal

179 Bromodeoxyuridine incorporation and fluorescence-activat

180 Diminished bromodeoxyuridine incorporation and increased TUNEL stai

181 h-dependent GNP proliferation as measured by bromodeoxyuridine incorporation and Nmyc expression.

182 ll density 1.5-fold (P < 0.05), confirmed by bromodeoxyuridine incorporation and proportionate increa

183 on kinetics of CD8+ T cells in the spleen by bromodeoxyuridine incorporation and their infiltration o

184 e degree of mitogenesis and cell survival by bromodeoxyuridine incorporation and trypan blue exclusio

185 to high fat feeding, evidenced by increased bromodeoxyuridine incorporation and villus lengthening,

186 us (DG) in the mdx mouse model of DMD, using bromodeoxyuridine incorporation as a marker of prolifera

187 e and CH157-MN cells by approximately 60% in bromodeoxyuridine incorporation assays.

188 proliferation was evaluated by detection of bromodeoxyuridine incorporation by immunohistochemistry.

189 a reduction of cells in G(1), inhibition of bromodeoxyuridine incorporation during S-phase, and a mo

190 Cell proliferation was measured by bromodeoxyuridine incorporation following p21(waf1/cip1)

191 stimulated both proliferation as measured by bromodeoxyuridine incorporation in basal epidermal cells

192 it(+) cell recruitment to BZ and the rate of bromodeoxyuridine incorporation in both c-kit(+) cells a

193 typic raft cultures indicated a reduction in bromodeoxyuridine incorporation in differentiated suprab

194 EZH2 had little to no effect on apoptosis or bromodeoxyuridine incorporation in GSCs, but it disrupte

195 ear antigen and Bcl-2 expression, as well as bromodeoxyuridine incorporation in prostate cancer cells

196 anded zone of PCNA expression, and increased bromodeoxyuridine incorporation in the PTK6-deficient sm

197 Consistent with this result, bromodeoxyuridine incorporation indicated that cellular

198 WT but not KO mice, 5-HT(4) agonists induced bromodeoxyuridine incorporation into cells that expresse

199 However, the maximal level of bromodeoxyuridine incorporation is reduced in dDP mutant

200 We analyzed the cell cycle by bromodeoxyuridine incorporation or propidium iodide stai

201 Immunolocalization and bromodeoxyuridine incorporation studies of adult SGZ in

202 he S phase of the cell cycle, as assessed by bromodeoxyuridine incorporation studies.

203 higher S-adenosylmethionine levels but lower bromodeoxyuridine incorporation than control cells.

204 hromosomes protein 1 (SMC1), postirradiation bromodeoxyuridine incorporation to evaluate S phase chec

205 Furthermore, when bromodeoxyuridine incorporation was compared at 11 sites

206 In vivo bromodeoxyuridine incorporation was elevated in DTG canc

207 As cell proliferation assessed by bromodeoxyuridine incorporation was higher in Rb(+/-)Ptt

208 Mechanical stretch-induced bromodeoxyuridine incorporation was reduced by 83.5% in

209 Inhibition of S-phase progression and bromodeoxyuridine incorporation were similarly induced b

210 sociated cushion cells displayed increased 5-bromodeoxyuridine incorporation when infected with Q79R-

211 ounts), proliferation (by flow cytometry and bromodeoxyuridine incorporation), cell viability (by try

212 nero mutations affect cell and organ size, bromodeoxyuridine incorporation, and autophagy.

213 sured using a combination of markers (Ki-67, bromodeoxyuridine incorporation, and phosphohistone H3)

214 ary ductal thickness as well as increases in bromodeoxyuridine incorporation, extracellular signal-re

215 sing a combination of in situ hybridization, bromodeoxyuridine incorporation, immunocolocalization, a

216 yte proliferation, as assessed by hepatocyte bromodeoxyuridine incorporation, phospho-histone H3 immu

217 ng independent parameters of regeneration, 5-bromodeoxyuridine incorporation, proliferating cell nucl

218 eases in the rate of cellular DNA synthesis, bromodeoxyuridine incorporation, protein synthesis, and

219 e cell (VSMC) proliferation, as reflected by bromodeoxyuridine incorporation, was markedly attenuated

220 Using bromodeoxyuridine incorporation, we show that the majori

221 the entry of cells into the cell cycle and 5-bromodeoxyuridine incorporation.

222 ctomy, and DNA replication was determined by bromodeoxyuridine incorporation.

223 roculture tetrazolium assay and by measuring bromodeoxyuridine incorporation.

224 60% increase in DNA synthesis as measured by bromodeoxyuridine incorporation.

225 is associated with a significant decrease in bromodeoxyuridine incorporation; an increase in senescen

226 ells; P < 0.01) and increased proliferation (bromodeoxyuridine incorporation; P < 0.001) of insulin-p

227 Bromodeoxyuridine-incorporation assays showed decreased

228 not parenchymal CD4(+) T cells incorporated bromodeoxyuridine, indicating local proliferation of CD4

229 kinetics were calculated using a cumulative bromodeoxyuridine injection protocol to determine the ef

230 Using bromodeoxyuridine injections at different time points du

231 nt assay (ELISA), measuring incorporation of bromodeoxyuridine into DNA.

232 There was significant incorporation of bromodeoxyuridine into smooth muscle cell DNA when treat

233 t inhibition of the in vivo incorporation of bromodeoxyuridine into the DNA of the cells in the subve

234 s well as by the diminished incorporation of bromodeoxyuridine into viral replication factories.

235 proliferation and migration, measured using bromodeoxyuridine, Ki-67, nestin, and doublecortin immun

236 ow that CVB3 targets actively proliferating (bromodeoxyuridine+, Ki67+) cells in the SVZ, including t

237 We also assessed the number of bromodeoxyuridine labeled dividing glial cells in the PF

238 Here, we show that bromodeoxyuridine-labeled and doublecortin-positive cell

239 nto anagen growth, confirmed by retention of bromodeoxyuridine-labeled bulge stem cells within the ha

240 Molecular combing of bromodeoxyuridine-labeled DNA revealed that once the Orc

241 and restitution was determined by assessing bromodeoxyuridine-labeled enterocytes along the crypt-vi

242 ctors increased the number of proliferating (bromodeoxyuridine-labeled) satellite cells in proximal a

243 Using in vivo bromodeoxyuridine labeling and in vitro functional assay

244 However, proliferation measured by in vivo bromodeoxyuridine labeling did not decline.

245 Bromodeoxyuridine labeling experiments show that lack of

246 s of epigenetic repressive marks, can retain bromodeoxyuridine labeling for a long time, and have col

247 s significantly increased liver mass and the bromodeoxyuridine labeling index compared with mice give

248 Bromodeoxyuridine labeling of dividing cells in 2-month-

249 Bromodeoxyuridine labeling of proliferating cells in the

250 Prox-1 immunohistochemistry and pulse-chase bromodeoxyuridine labeling showed that progenitors migra

251 nd ES cell-derived cardiomyocytes based on 5-bromodeoxyuridine labeling was similar, and immunocytoch

252 Colorectal tumor number and bromodeoxyuridine labeling were determined in Rosa26-Fox

253 cells using sucrose gradient sedimentation, bromodeoxyuridine labeling, chromatin immunoprecipitatio

254 Bromodeoxyuridine labeling, followed by immunoprecipitat

255 Bromodeoxyuridine labeling, in situ hybridization, and i

256 cell counting, cell proliferation assay, and bromodeoxyuridine labeling.

257 idine-labeled cells and confocal analysis of bromodeoxyuridine labeling.

258 However, pulse-chase 5-bromodeoxyuridine-labeling assay revealed that the senes

259 tate tumorigenesis lastingly coexistent with bromodeoxyuridine-labeling neoplastic lesions, revealing

260 escence showed a 95% co-localization of anti-bromodeoxyuridine labelling with apoptotic markers, demo

261 own that accumulation of recently recruited (bromodeoxyuridine(+) MAC387(+)) monocytes is associated

262 ar and paraventricular zones, the density of bromodeoxyuridine-, NeuN-, and doublecortin-labeled cell

263 Analysis by bromodeoxyuridine-nuclear labeling showed decreased inco

264 Intensity ratios of binucleated CPCs with bromodeoxyuridine of >/=70:30 between daughter nuclei in

265 i67), maturation (doublecortin) or survival (bromodeoxyuridine) of new adult-born hippocampal neurons

266 In addition, some GBCs retain bromodeoxyuridine or ethynyldeoxyuridine for an extended

267 or without a running wheel and injected with bromodeoxyuridine or retrovirus to label newborn cells.

268 A greater percentage of SMMs was bromodeoxyuridine positive (SMMs versus LBMs: 3.1% versu

269 rophages derived from circulating monocytes (bromodeoxyuridine positive [BrdU(+)] CD163(+)), suggesti

270 l proliferation (400 +/- 81 vs. 2630 +/- 390 bromodeoxyuridine-positive cells mm(-2) in controls, P <

271 Teduglutide increased bromodeoxyuridine-positive cells vs untreated controls b

272 euron-specific nuclear protein)-positive and bromodeoxyuridine-positive cells.

273 enesis evident by the reduction in number of bromodeoxyuridine-positive, Ki-67(+), and doublecortin(+

274 anti-phospho-Histone H3 immunoreactivity and bromodeoxyuridine pulse labelling.

275 Prior to tail loss, we performed a bromodeoxyuridine pulse-chase experiment and found that

276 Bromodeoxyuridine pulse-chase experiments with short sur

277 Utilizing in vivo imaging and bromodeoxyuridine pulse-chase experiments, we have analy

278 ectron microscopy, immunohistochemistry, and bromodeoxyuridine pulse-chase experiments.

279 Pulse-labeling of progenitors with bromodeoxyuridine showed that, as with surgical bulb rem

280 Application of bromodeoxyuridine significantly reduced cell damage, all

281 liferation and apoptosis were assessed using bromodeoxyuridine staining and terminal deoxynucleotidyl

282 Bromodeoxyuridine staining of papillomas and adjacent ep

283 -systolic pressure, right ventricular dP/dt, bromodeoxyuridine staining, or pulmonary artery medial w

284 h muscle cell proliferation as determined by bromodeoxyuridine staining.

285 chromatids was documented by clonal assay of bromodeoxyuridine-tagged hCSCs.

286 lated by cautery and animals were exposed to bromodeoxyuridine then examined following short (4-hour)

287 aily injections of the cell birthdate marker bromodeoxyuridine throughout puberty (postnatal day 28-4

288 current study, we used in vivo labeling with bromodeoxyuridine to characterize the kinetics of naive,

289 Cells were labeled with bromodeoxyuridine to detect proliferation, and indirect

290 f acetaminophen administered coincident with bromodeoxyuridine to load possible hepatic stem cells in

291 Bromodeoxyuridine uptake assay showed that cerebral hypo

292 howed decreased proliferation as measured by bromodeoxyuridine uptake, which was confirmed by bluntin

293 Cell proliferation was measured by bromodeoxyuridine uptake.

294 ediated Tcf/Lef transcriptional activity and bromodeoxyuridine uptake.

295 trating T-cell proliferation was measured by bromodeoxyuridine uptakes, whereas their apoptosis was q

296 The thymidine analogue bromodeoxyuridine was administered to assess the degree

297 abeling of mitotic cells in the hippocampus, bromodeoxyuridine was injected into the peritoneal cavit

298 One month after irradiation, bromodeoxyuridine was injected intraperitoneally for sev

299 tibility to the thymine nucleoside analogue, bromodeoxyuridine, was reduced.

300 portion of newly generated oligodendrocytes (bromodeoxyuridine+) were PPAR-delta+.